The decision to adopt AI diagnostic tools in your radiology department is no longer speculative. It is operational. What trips up most healthcare IT directors and radiology leaders is not the concept but the contract: how do you evaluate which AI imaging vendor deserves a spot in your clinical workflow before you commit?
This post skips the primer on what AI can do for radiology. If you want that background, the posts on AI in medical imaging diagnostics and the benefits of AI-powered PACS cover it well. What follows is a procurement framework built around seven evaluation criteria that separate vendors worth piloting from ones that will cost you time, budget, and radiologist trust.
A Seven-Criterion Framework for Evaluating AI Diagnostic Tools
1. FDA Clearance Status
FDA clearance is the minimum bar, not the finish line. The FDA maintains a publicly searchable list of AI-enabled medical devices that have met premarket requirements, which now includes over 1,400 devices. Before you proceed with any vendor evaluation, confirm your candidate tool appears on this list with a 510(k) clearance or De Novo authorization for the specific clinical indication you need.
Clearance tells you the FDA reviewed the tool for its stated use. It does not tell you how the tool performs on your patient population, your scanner hardware, or your imaging protocols. That distinction matters enormously in clinical settings with non-standard patient demographics or legacy acquisition equipment. Use clearance as a gate to entry, then apply the remaining criteria to determine fit.
One practical note: some vendors market AI tools as “FDA-registered” or “FDA-compliant,” which are not the same as cleared. Registered means the device is listed in the FDA database; cleared or authorized means it has gone through premarket review. Ask vendors directly which designation applies to each algorithm they sell.
2. Clinical Validation Evidence
Regulatory clearance is backward-looking. Clinical validation evidence is forward-looking: it tells you how the tool performs in conditions similar to yours.
Ask every vendor for peer-reviewed performance data, not marketing slides. The data should specify sensitivity and specificity on a prospective dataset, not just a training set. The gap between training performance and real-world performance is where most AI failures live. A 2024 multi-society statement from the ACR, ESR, RANZCR, and RSNA on AI procurement considerations for radiology specifically recommends that purchasers evaluate whether FDA clearance data reflects accuracy on local patient data and whether local validation is feasible.
That last point is actionable. Many vendors now offer a structured pilot period (typically 30 to 90 days) where their algorithm runs in shadow mode on your existing case volume. This lets you measure sensitivity, specificity, and false positive rates against your own radiologists’ reads before the tool influences any clinical decision. If a vendor resists this kind of pilot, treat that resistance as a signal.
3. Integration Footprint
An AI diagnostic tool is only useful if it fits inside your actual workflow. Integration complexity is one of the most underestimated procurement risks in radiology.
There are three integration layers to evaluate. First, the modality layer: does the tool accept DICOM data directly from your scanners, or does it require a proprietary gateway? Second, the PACS layer: does the tool embed findings into your existing viewer, or does it open a separate interface that forces radiologists to toggle between screens? Third, the reporting layer: does the tool populate structured report fields in your RIS, or does it output free-text findings that someone has to manually transcribe?
Workflow disruption correlates directly with radiologist adoption. Tools that add steps rather than remove them tend to be quietly ignored within weeks of deployment. OmniPACS integrates AI-derived findings directly into the reading workflow, so radiologists see algorithmic flags alongside native DICOM images, with no secondary screens or manual data entry required. When evaluating vendors, map their integration architecture to your current PACS stack and request a live demonstration using your scanner output, not a generic demo dataset.
4. Workflow Disruption Assessment
Separate from the integration architecture is the question of how the tool changes the reading workflow itself. These are related but distinct.
A tool can be technically integrated into your PACS but still disrupt the workflow by injecting alerts at the wrong point in the reading sequence, requiring radiologists to actively dismiss flags before continuing, or slowing image load times. Each of these creates friction. Research on AI adoption in clinical radiology consistently shows that automation bias (where radiologists over-rely on AI flags) and alert fatigue are two of the most significant failure modes. Both arise from poor workflow design, not poor AI performance.
When you run a pilot, track the following: How many clicks does the tool add per study? How often do radiologists override AI findings, and how long does that take? Does the tool change the sequence in which studies are read? Does it affect overall read time per study, and in which direction? OmniPACS includes usage analytics that automatically surface these metrics during the pilot period, so your team does not need to manually instrument the workflow to collect data.
5. Pricing Model and Total Cost
AI imaging tools are priced in at least four distinct ways: per-study subscription, annual site license, per-user license, or a bundled fee embedded in a broader PACS or platform contract. Each model has different implications for your volume projections and budget flexibility.
Per-study pricing is straightforward to model, but can become expensive if your study volume grows faster than projected. Site licenses offer cost predictability but may include modality or specialty restrictions that limit where the tool can be deployed. Bundled pricing inside a platform contract can obscure the true cost of the AI component, which matters when the time comes to renegotiate or switch vendors.
Ask vendors to provide a total cost of ownership model that includes implementation fees, HL7/DICOM integration work, training costs, and the ongoing monitoring and update cadence. Also, ask whether model updates are included in the contract or priced separately. Model updates are essential for maintaining performance as scanner technology and imaging protocols evolve. OmniPACS offers flexible monthly plans that include model updates and technical support, without per-study surprise charges, simplifying multi-year budget planning.
If you want to understand how PACS pricing models work broadly before entering vendor negotiations, the post on PACS cost structures and pricing models covers the landscape in detail.
6. ROI Measurement Plan
No AI procurement decision should close without a defined ROI measurement plan. This is not paperwork. It is the only way to know whether the tool is delivering value or just consuming budget.
Define your ROI metrics before you sign, not after. Typical metrics in radiology AI procurement include: reduction in mean time to diagnosis for the tool’s target condition, change in radiologist throughput per shift, reduction in call-back or repeat-imaging rates triggered by missed findings, and change in downstream care pathway costs for the conditions the tool addresses.
Pair each metric with a baseline measurement from your current workflow, so you have something to compare against. A vendor that cannot tell you how to measure the tool’s impact on your specific use case is either not tracking outcomes or does not have favorable outcomes to share. Either is worth knowing before you sign.
7. Vendor Stability and Roadmap
The AI radiology vendor market is active and, in some segments, consolidating. Startups with impressive demo-day algorithms have been acquired, pivoted, or shut down so quickly that procurement teams have been left holding contracts for tools that have received no further updates. Before you commit, run basic due diligence on vendor stability.
Ask how long the company has been operating, how many sites are actively deployed (not contracted, deployed), and what the product roadmap looks like for the next 12 to 18 months. Find out who owns the training data used to build the model and whether data governance agreements exist that protect your patient data in the event of an acquisition or shutdown. Ask specifically what will happen to your integration and historical outputs if the vendor is acquired.
OmniPACS works with AI vendors who meet these stability criteria and has built its integration architecture so that AI modules can be swapped out without disrupting the underlying PACS workflow. This is a meaningful technical safeguard against vendor lock-in.
Putting the Framework Together
A complete AI imaging vendor evaluation runs these seven criteria in roughly the order listed: clearance and validation first (gate criteria), then integration and workflow (fit criteria), then pricing and ROI (investment criteria), and finally vendor stability (risk criteria). Most healthcare IT teams find that applying this sequence reduces the shortlist from a dozen vendors to two or three within two weeks.
The evaluation also surfaces questions your radiologists need to answer alongside IT, and it is worth running the framework as a joint team exercise. Radiologists are the people who will work with the tool every day. Their assessment of workflow disruption in a pilot is more reliable than any vendor benchmark.
If you are early in the process of building an AI-ready imaging infrastructure, the post on medical imaging technology trends shaping radiology provides useful context on where AI capabilities are heading and which investment categories have the clearest clinical evidence behind them.
For teams that are ready to move from evaluation to deployment, OmniPACS offers a structured onboarding process that covers integration assessment, workflow mapping, and pilot configuration before any contract is signed. To learn more about how OmniPACS structures AI-ready PACS implementations, explore OmniPACS solutions, and see which configuration fits your facility’s size and specialty mix.
Frequently Asked Questions
What is the difference between FDA-cleared and FDA-approved for AI tools?
FDA-cleared means a device went through the 510(k) premarket notification process and was found substantially equivalent to a legally marketed predicate device. FDA-approved means it went through the more rigorous Premarket Approval pathway, typically for higher-risk devices. Most radiology AI tools are cleared, not approved. A smaller number have received De Novo authorization, which establishes a new regulatory category. All three pathways indicate FDA review; the differences relate to evidentiary requirements and device risk classification.
How long should an AI imaging pilot run?
Most radiology teams run pilots between 30 and 90 days in shadow mode, where the AI tool analyzes studies and generates findings but does not surface those findings to radiologists in real time. This lets you collect clean performance data without influencing clinical reads during the evaluation period. After shadow mode, a shorter supervised integration phase of 2 to 4 weeks lets radiologists interact with the tool in a controlled setting before full deployment.
Can AI imaging tools be integrated with any PACS?
Most modern AI tools are designed to work with standard DICOM workflows, which gives them broad PACS compatibility in principle. In practice, the depth of integration varies significantly between vendors and PACS platforms. Some tools offer deep embedding, where findings appear as structured annotations directly in the viewer, while others output results as secondary captures or external reports that require the radiologist to leave their primary workspace. Ask your PACS vendor and your AI vendor to confirm integration depth with a live demonstration on your specific platform version.
What happens to AI model performance over time?
AI models trained on a fixed dataset can experience “model drift” as real-world conditions diverge from those during training. Scanner hardware upgrades, protocol changes, and population shifts can all degrade performance gradually. Responsible vendors monitor production performance and issue model updates on a defined schedule. Confirm in your contract how often models are updated, how updates are tested before deployment, and whether you are notified of performance changes between update cycles.
How does OmniPACS handle AI tool integration?
OmniPACS integrates AI diagnostic tools at the DICOM routing level, which means AI analysis runs in parallel with image transmission to the viewer rather than as a sequential step that adds to read time. Findings surface inside the native reading environment as structured overlays, so radiologists do not need to leave their primary workspace. OmniPACS also provides the usage analytics needed to measure adoption rates and pilot outcomes. Check out OmniPACS services to see the full integration architecture and available AI modules.